Hemmer B, Vergelli M, Tranquill L, Conlon P, Ling N, McFarland H F, Martin R
Neuroimmunology Branch, NINDS, National Institutes of Health, Bethesda, MD 20892-1400, USA.
Neurology. 1997 Oct;49(4):1116-26. doi: 10.1212/wnl.49.4.1116.
Multiple sclerosis (MS) is considered a T cell-mediated autoimmune disease, and myelin proteins are the most likely candidate autoantigens. Based on experiments performed in experimental allergic encephalomyelitis (EAE), innovative immunotherapies have been developed that target either the specific trimolecular complex of encephalitogenic T cells, consisting of T-cell receptor (TCR), major histocompatibility complex (MHC; HLA in humans) class II molecule, and autoantigenic peptide, or the effector functions of these cells. To provide the basis for the transfer of these specific immunotherapies to MS, we extensively characterized the human T-cell response to one major myelin epitope, the myelin basic protein peptide (83-99). We analyzed restriction element, TCR usage and affinity, fine specificity, cytokine production, cytolytic activity, and expression of surface molecules on 41 T-cell clones (TCCs) derived from MS patients and normal controls. We demonstrate a high degree of complexity of recognition patterns as well as of functional phenotypes among T cells responding to the same epitope. In contrast to results from animal models, these findings indicate that the design of epitope-based specific immunotherapies for MS is more difficult than previously thought.
多发性硬化症(MS)被认为是一种T细胞介导的自身免疫性疾病,髓磷脂蛋白是最有可能的自身抗原候选物。基于在实验性变应性脑脊髓炎(EAE)中进行的实验,已经开发出了创新的免疫疗法,这些疗法要么针对致脑炎性T细胞的特定三分子复合物(由T细胞受体(TCR)、主要组织相容性复合体(MHC;人类中的HLA)II类分子和自身抗原肽组成),要么针对这些细胞的效应功能。为了为将这些特异性免疫疗法应用于MS提供依据,我们广泛地对人类T细胞对一种主要髓磷脂表位,即髓磷脂碱性蛋白肽(83-99)的反应进行了表征。我们分析了来自MS患者和正常对照的41个T细胞克隆(TCC)的限制性元件、TCR使用情况和亲和力、精细特异性、细胞因子产生、细胞溶解活性以及表面分子的表达。我们证明了对同一表位作出反应的T细胞之间识别模式以及功能表型的高度复杂性。与动物模型的结果相反,这些发现表明,针对MS的基于表位的特异性免疫疗法的设计比以前认为的更加困难。